American Society of Gene & Cell Therapy

03/13/2026

Congratulations to R. Jude Samulski, Ph.D., recipient of the 2026 ASGCT Founders Award! From the original cloning of AAV to pioneering gene delivery to the central nervous system, Dr. Samulski’s contributions have been instrumental in shaping the cell and gene therapy field.

Join us in celebrating this true pioneer at !

Learn more about our 2026 award winners: https://www.asgct.org/news-publications/asgct-news/congratulations-to-our-2026-honorific-and-funded-award-winners

03/13/2026

📣 Last call! Submit your groundbreaking, high-impact research for a chance to present at : https://annualmeeting.asgct.org/abstracts/submission-information/late-breaking-abstracts

03/12/2026

"A superpower this community shares is telling others how they did it – tap into that collective experience that exists in the rare disease space." –Joe Katakowski, PhD

That's a wrap on Day 1 of the Empowering Patients Summit! 🎉 We kicked things off with Dr. Steven Gray breaking down CGT science and Dr. Allison Bradbury on the power of strategic partnerships. We closed with an incredible Catalysts in Action panel, where leaders shared how patient groups like RTW Foundation, Elly's Team, and TESS Research Foundation for Slc13a5 Epilepsy move the needle for their communities every day.

Missed today? You can still join us tomorrow for Day 2! We’ll be diving into N of 1 therapies and hearing from our Patients are the Experts panel.

Register for free to catch the final day: asgct.org/empowering

03/11/2026

The March 2026 issue of The Advocate is out! 🗞️ This month:
🔹 FDA launches a new framework for bespoke, individualized therapies.
🔹 ASGCT urges the Senate to align regulatory expectations with the biological realities of rare disease.
🔹 New webinar series: What to know before your next PPQ campaign.

Stay ahead of the evolving regulatory landscape. Read more + subscribe:

ASGCT joins bipartisan sign-on letters supporting the reauthorization of the C.W. Bill Young Transplant Program and robust FY27 funding for NIH ($51.3B)…

03/10/2026

Exciting new addition to the Empowering Patients Summit! 📢

Join us for a live Q&A with ASGCT CEO David Barrett as he dives into the Society’s newest initiatives. Building on Day 1’s announcements, this session explores how CGTxchange, the ASGCT Foundation, and our new developer consortium are bridging critical gaps in therapy development for patient communities.

Don't miss this look at the future of CGT advocacy and access! Register for the free virtual Summit (March 11–12 and on demand): asgct.org/empowering

03/08/2026

"Molecular Therapy for me has always been one of those journals that I just really highly respect the work coming out of it. What we're really looking to do is make it the home where people go for their cutting-edge RNA research." – Anna Blakney, Ph.D.

03/06/2026

Congratulations to Beverly L. Davidson, Ph.D., recipient of the 2026 ASGCT Outstanding Achievement Award! As the Society’s highest honor, this award recognizes Dr. Davidson’s pioneering research into the molecular mechanisms of inherited brain diseases and her leadership in developing and testing gene-based therapeutic strategies.

Join us in celebrating her incredible contributions to the field at ! Meet all of our 2026 award winners: https://www.asgct.org/news-publications/asgct-news/congratulations-to-our-2026-honorific-and-funded-award-winners

03/05/2026

“I don’t think it’s exaggerating to say that this is the future of medicine.” – Dr. Kiran Musunuru

We are thrilled to welcome TIME100 Health honoree Kiran Musunuru, MD, Ph.D., MPH, ML, MRA (University of Pennsylvania), to the Empowering Patients Summit this week!

Fresh off his groundbreaking work developing a world-first customized CRISPR therapy for an infant with a rare genetic mutation, Dr. Musunuru joins Olivia Kim-McManus, MD (Rady Children's Hospital-San Diego), to explore The Realities of N of 1 and Implications for the Patient Community.

Don’t miss this deep dive into the promise and complexities of individualized gene therapies and what they mean for the future of ultra-rare disease advocacy.

Join us for this free, virtual event (March 11+12): asgct.org/empowering

03/04/2026

Ready to dive deep into the latest in CGT? 🧬 Enhance your experience by adding a specialized workshop to your registration! Taking place Monday, May 11, these four-hour intensive sessions cover the field’s most pressing topics:

Precision gene editing and HDR in translation
Automation in manufacturing and QC
Viral gene therapy targeting and detargeting
Cell therapy at the clinical frontier
Stakeholder engagement in translational research

ASGCT members save $50 on workshop registration! Secure your spot for these deep-dive sessions today: annualmeeting.asgct.org/workshops

03/02/2026

How is gene therapy being used to target Angelman syndrome? 🧠 Explore our new free educational resource to learn about the current treatment pipeline, the challenges of delivery to the brain, and more. Includes a free downloadable infographic!

Dive in: https://patienteducation.asgct.org/understanding-cell-gene-therapy/conditions-treated/neurologic-disorders/angelman-syndrome

Thank you to Ultragenyx for supporting this content!

Angelman syndrome (AS) is a rare genetic disorder that affects the nervous system and causes developmental delays. This unit will explore the condition…

02/28/2026

On , we honor the resilience of those living with rare conditions and the families who champion their care. At the heart of every breakthrough is a patient expert navigating uncertainty with hope.

Join us at the Empowering Patients Summit (March 11+12) to hear these stories firsthand. Our closing session centers the lived experiences of the rare disease community, sharing the real highs and lows of the cell and gene therapy journey and what it takes to navigate the road to treatment.

RSVP to secure your spot at this free virtual event: asgct.org/empowering

02/27/2026

Ahead of , ASGCT CEO David Barrett spoke with Gerron Jordan TV at WISN 12 NEWS about the realities facing the 1 in 10 Americans living with a rare disease and the hope offered by emerging cell and gene therapies.

David emphasized how ASGCT’s education resources play a crucial role in connecting patients with trusted information and support, which is an essential need as thousands of cell and gene therapies continue moving through development. With the demand for reliable guidance only growing, ASGCT remains dedicated to educating and empowering patients, families, and clinicians.

Watch the conversation:

With 300 million people living with rare diseases, experts say new gene and cell therapies are giving families in Wisconsin hope for lasting treatment options.